Stroke Was Third Most Common GBD Level 3 Cause of Death in 2021
By Elana Gotkine HealthDay Reporter
FRIDAY, Sept. 20, 2024 -- The global burden of stroke is considerable, according to a study published in the October issue of The Lancet Neurology.
Valery L. Feigin, M.D., Ph.D., from the Auckland University of Technology in New Zealand, and colleagues estimated the incidence, prevalence, death, and disability-adjusted life-year (DALY) counts and age-standardized rates per 100,000 per year for stroke for 204 countries and territories from 1990 to 2021.
The researchers found that stroke was the third most common Global Burden of Disease (GBD) level 3 cause of death in 2021 (7.3 million deaths; 10.7 percent of all deaths), after ischemic heart disease and COVID-19. Stroke was the fourth most common cause of DALYs (160.5 million DALYs; 5.6 percent). There were 93.8 million prevalent and 11.9 million incident strokes in 2021. There were disparities observed in stroke burden and risk factors by GBD region, country or territory, and sociodemographic index; in addition, from 2015 onward, there was a stagnation in the reduction of incidence. Some increases in the stroke incidence, death, prevalence, and DALY rates were seen in specific regions and subpopulations. Substantial increases were seen in DALYs attributable to high body mass index, high ambient temperature, high fasting plasma glucose, diet high in sugar-sweetened beverages, low physical activity, high systolic blood pressure, lead exposure, and diet low in omega-6 polyunsaturated fatty acids.
"Our study findings continue to point out that currently used stroke prevention strategies are not sufficiently effective to halt, let alone reduce, the fast growing stroke burden," the authors write.
Several authors disclosed ties to the biopharmaceutical industry.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2024-09-21 12:00
Read more
- Elevar Therapeutics Announces FDA Acceptance of New Drug Application Resubmission for Rivoceranib in Combination with Camrelizumab as a First-line Systemic Treatment for Unresectable Hepatocellular Carcinoma
- Global TB Cases Hit Record High, TB Becomes Top Infectious Disease Killer
- Oct. 7 Tragedy Spurs Israeli Researcher to Study Grief Over Sibling Loss
- Measures of Social Support Linked to Cancer Screening
- Flu-Linked Hospitalization Rates Vary Across Seasons, Highest in Adults 65+
- Sangamo Therapeutics Announces Alignment With FDA on Accelerated Approval Pathway for ST-920 in Fabry Disease With BLA Submission Expected in 2025
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions